A related editorial discusses the implications of these finding, highlighting that “these data cannot inform clinical practice guidelines regarding appropriate levels for initiation of blood pressure–lowering therapy or goal levels for treatment. However, these data strengthen the case to lower the risk for cardiovascular diseases in those with SBP of 140 mmHg or higher by all effective means available, including improving uptake of healthy diets, minimising weight gain or promoting weight loss in overweight and obese individuals, and promoting uptake and adherence to effective blood pressure–lowering drugs as well as management of related cardiovascular risk”.